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Superantigens (SAgs) are a family of potent immunostimulatory exotoxins known to be
produced by only a few bacterial pathogens, including Staphylococcus aureus. More than
20 distinct SAgs have been characterized from different S. aureus strains and at least 80%
of clinical strains harbor at least one SAg gene, although most strains encode many. SAgs
have been classically associated with food poisoning and toxic shock syndrome (TSS), for
which these toxins are the causative agent. TSS is a potentially fatal disease whereby
SAg-mediated activation of T cells results in overproduction of cytokines and results in
systemic inflammation and shock. Numerous studies have also shown a possible role for
SAgs in other diseases such as Kawasaki disease (KD), atopic dermatitis (AD), and chronic
rhinosinusitis (CRS). There is also now a rich understanding of the mechanisms of action
of SAgs, as well as their structures and function. However, we have yet to discover what
purpose SAgs play in the life cycle of S. aureus, and why such a wide array of these toxins
exists. This review will focus on recent developments within the SAg field in terms of the
molecular biology of these toxins and their role in both colonization and disease.
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INTRODUCTION
Bacterial superantigens (SAgs) represent a unique class of exo-
toxins which all function to activate enormous numbers of T
lymphocytes (McCormick et al., 2001; Llewelyn and Cohen,
2002; Proft and Fraser, 2003). Although only a few SAgs
have clear associations with specific human diseases, bacterial
genome sequencing projects over the last decade have led to the
characterization of a large and expanding family of exotoxins
that includes many genetically and antigenically distinct pro-
teins. These are found primarily in Staphylococcus aureus and
Streptococcus pyogenes, but also found in a few other species
of β-hemolytic streptococci, coagulase negative staphylococci,
Mycoplasma arthritidis, and Yersinia pseudotuberculosis. In the
following sections, we will update recent findings in the biochem-
istry of staphylococcal SAgs, and explore the role of SAgs in differ-
ent lifestyles of S. aureus in the context of both infection and nasal
colonization.
THE SUPERANTIGEN SUPERFAMILY
The staphylococcal SAgs include the staphylococcal enterotox-
ins (SEs), the staphylococcal enterotoxin-like (SEls) proteins, and
toxic shock syndrome toxin-1 (TSST-1) (Lina et al., 2004). The
SEs were originally defined by their ability to cause staphylococ-
cal food poisoning (SFP) including emesis, and currently include
the SEs A, B, C, D, E, G, H, I, R, and T. The SEl toxins, although
both homologous and structurally similar to the SEs, either do
not induce emesis, or have not been formally demonstrated to
induce emesis, and include the SEls J, K, L, M, N, O, P, Q, S, U, V,
and X. It is important to note that although designated as a “SEl”
toxin, some of these may possess undemonstrated emetic activity
and be reclassified in the future as bona fide enterotoxins.
An updated phylogenetic classification scheme of the SAg exo-
toxins (McCormick et al., 2001) is shown in Figure 1 where SAgs
from staphylococci and streptococci are placed into five evo-
lutionary groups. TSST-1 sits as an evolutionarily distinct SAg
that does not induce emesis (Schlievert et al., 2000) and is the
only member of the Group I SAgs. TSST-1 is believed to be the
major, if not sole cause of the menstrual form of toxic shock
syndrome (TSS) (Bergdoll et al., 1981; Schlievert et al., 1981).
The Group II SAgs contain both staphylococcal and streptococcal
SAgs including SEB, SEC, and streptococcal pyrogenic exotoxin A
(SpeA). After TSST-1, SEB has been historically most commonly
linked with non-menstrual-associated cases of staphylococcal TSS
(Schlievert, 1986), while SpeA has been historically most com-
monly linked with streptococcal TSS (Stevens et al., 1989). The
Group III SAgs include only staphylococcal SAgs, and in gen-
eral terms, this Group contains SAgs most commonly associated
with SFP such as SEA, SED, and SEE, although the Group II SAgs
SEB and SEC are often implicated as well (Argudin et al., 2010).
Both Group II and III SAgs contain a unique “cysteine-loop struc-
ture” that is important for emetic activity (Hovde et al., 1994).
The Group IV SAgs are only populated by streptococcal SAgs and
will not be discussed here. The Group V SAgs, contain mostly
staphylococcal SAgs (except SpeI and related orthologues), and
other than SEI which has weak emetic activity, consists of only
SEl toxins. In fact, SEI is the only SAg outside of the Group II and
III SAgs demonstrated to have emetic activity, although this only
occurred in one of four animals tested (Munson et al., 1998). Very
recently, SEl-X was described as a novel SAg that does not align
well within the currently classification system, but is encoded
within the core chromosome of most S. aureus strains (Wilson
et al., 2011). Also of note are the staphylococcal superantigen-like
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proteins (SSLs) (Langley et al., 2010), and although these are also
structurally similar to the staphylococcal superantigens (Baker
et al., 2007; Chung et al., 2007; Ramsland et al., 2007) they
do not possess SAg activity and will not be discussed within
this review.
FIGURE 1 | Phylogenetic tree of known bacterial SAgs. The unrooted
tree was based on the alignment of amino acid sequences constructed
with the unweighted pair group method using arithmetic averages
(UPGMA) in MacVector 7.2.3. The SAg abbreviations are indicated followed
by the relevant accession number. As previously proposed (McCormick
et al., 2001), the five main groups of SAgs belonging to the pyrogenic toxin
class are indicated. MAM, YPM, and non-Group A streptococcal SAgs are
also included in the analysis. The number of times each branch was
supported from 1000 bootstraps is shown as a percentage.
CONVENTIONAL VERSUS SUPERANTIGEN-MEDIATED
T CELL ACTIVATION
Normal T cell-mediated immunity is initiated through the inter-
action of an αβ T cell receptor (TCR) and a processed peptide
antigen presented within self-major histocompatibility (pMHC)
complexes (Figure 2A) (Garcia et al., 1999; Garcia and Adams,
2005). If the TCR specifically recognizes the antigen as foreign,
these interactions will activate the tyrosine kinase Lck (associ-
ated with co-receptors CD4 and CD8), which in turn will activate
downstream cell signaling resulting in activation of transcrip-
tion factors to induce T cell proliferation and differentiation
(Smith-Garvin et al., 2009). As TCRs are extraordinarily diverse
molecules, only ∼0.01% of naïve T cells will recognize a given
antigen (Givan et al., 1999).
SAg-mediated T cell activation is both quantitatively and qual-
itatively distinct from conventional T cell activation (Bueno et al.,
2007). As the defining feature of the SAg toxin is the ability
to activate T lymphocytes in a TCR β-chain variable domain
(Vβ)-dependent manner (Marrack and Kappler, 1990), very large
FIGURE 2 | Structural overview of the SAg-mediated T cell activation
complexes. Ribbon diagram models show (A) conventional T cell activation
(Hennecke et al., 2000), and SAg-mediated T cell activation complexes for
(B) Group I (e.g., TSST-1) (C) Group II (e.g., SEB) (D) Group III (e.g., SEH)
and (E) Group V (e.g., SEl-K). Colors for TCR and MHC class II chains are
labeled in Panel (A). The SAg activation complex models were generated by
superposition of the TSST-Vβ (Moza et al., 2007) and TSST-MHC class II
(Kim et al., 1994) structures, the SEC-Vβ (Fields et al., 1996) and SEB-MHC
class II (Jardetzky et al., 1994) structures, the SEH-VαVβ (Saline et al.,
2010), SEH-MHC class II β-chain (Petersson et al., 2001), and the SEA-MHC
class II α-chain (Petersson et al., 2002) structures, and the SEK-Vβ (Gunther
et al., 2007) and SEI-MHC II (Fernandez et al., 2006) structures. The TCR
α-chain was modeled for clarity in each case from the conventional complex
(Hennecke et al., 2000). The “?” in Panel (E) indicates that there is no
current information regarding the presence, or absence, of the generic
low-affinity MHC class II binding domain for Group V SAgs.
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numbers of T cells can be activated upon SAg exposure. Although
TCRs are extraordinarily diverse molecules, this diversity is
concentrated within the CDR3 loops due to V(D)J (somatic)
recombination during T cell development. However, there are a
relatively limited number of possible TCR Vβ regions (∼50 are
functionally expressed in humans), and thus SAgs can activate
T cells in orders of magnitude above conventional processes. SAgs
also do this in an extremely potent manner, and in general, most
SAgs can induce measurable activation of T cells in the picogram
(10−12 g) concentration range. It is often assumed that SAg-
mediated T cell activation follows the normal signaling rules for
conventional pMHC-mediated T cell activation and indeed this
is the case with at least one major distinction. As predicted, TCR
ligation by SAg will induce signals through Lck (Morgan et al.,
2001), although Lck signaling is not actually required (Yamasaki
et al., 1997; Bueno et al., 2006). However, signaling can proceed
in the absence of Lck through a Gα11/PLCβ-dependent pathway
that converges with the canonical Lck-dependent pathway at the
level of ERK1/2 (Bueno et al., 2006). Since one function of the
CD4/CD8 co-receptors is the recruitment of Lck, the ability of
SAgs to bypass Lck is also likely related to the capability of SAgs
to activate both CD4+ and CD8+ T cells, despite cross-linking
with MHC class II molecules (Herrmann et al., 1992; Fuller and
Braciale, 1998).
The human immune system has evolved to be able to recognize
and eliminate pathogens and their antigens. However, SAgs rep-
resent the only known microbial virulence factor whose primary
role is to deliberately force the activation of the adaptive immune
system. This is counter-intuitive given the numerous staphylococ-
cal virulence factors apparently designed for immune subversion
and evasion (Nizet, 2007). This leads to the question as to why
S. aureus produce SAgs. Given the wide variety and high preva-
lence of SAg genes, it is likely that these genes would be lost,
especially since they are primarily encoded on mobile genetic ele-
ments, without a contribution to the fitness of S. aureus. The
influence and architecture of SAg-encoding mobile genetic ele-
ments has been the subject of a comprehensive review in this issue
(McGavin et al., 2012).
T cell anergy, a phenomenon where T cells become unrespon-
sive to stimulation, has long been proposed to be an immune
subversion tactic of S. aureus. Several studies have shown this
ex vivo following in vivo stimulation (Kawabe and Ochi, 1990;
Rellahan et al., 1990; Lee and Vitetta, 1992; Miller et al., 1999).
However, SAg-induced anergy produced ex vivo does not neces-
sarily translate into in vivo anergy (Heeg et al., 1995). In addition,
high levels of purified toxin are often used in experimental mouse
models that may not reflect physiological conditions. Also, there
is no evidence to suggest that T cells are exhausted in nasal
carriers of toxigenic S. aureus strains. Recently, a case study
of TSS (likely induced by TSST-1) showed deletion followed
by an expansion in the Vβ2+ subset that normalized 70 days
post-convalescence. In this important study, re-stimulation of
peripheral blood mononuclear cells (PBMCs) taken during the
acute phase of disease with exogenous SAg resulted in prolifer-
ation of Vβ2+ cells suggesting that T cells were not rendered
anergic (Rasigade et al., 2011). Recurrent cases of TSS occur, usu-
ally as a combined result of insufficient eradication of S. aureus
and the inability to form anti-SAg antibodies. The proliferative
response of T cells was assessed from a patient with recurrent TSS
and there was no reduction in the ability of the patients T cells to
respond in vitro (Arvand and Hahn, 1996). Thus, at least in some
patients, true anergy of Vβ specific T cell subsets may not occur
and suggests that this activity is not the purpose of SAg activity
for S. aureus. Recurrent TSS also implies that T cells are not ren-
dered anergic as they are able to react to SAg stimulation during
multiple episodes.
Recently, Taylor and Llewelyn (2010) demonstrated that
human PBMCs exposed to SAgs resulted in a dose-dependent, Vβ
specific increase in CD25+ FoxP3+ cells, indicative of a regula-
tory T cell (Treg) phenotype. The immunosuppressive qualities of
these SAg-induced Tregs have been attributed to the expression of
IL-10 and may have a role in prolonging commensalism (Taylor
and Llewelyn, 2010).
STAPHYLOCOCCAL SUPERANTIGENS AND THEIR
HOST RECEPTORS
SAg pro-toxins include a secretion signal that is cleaved from the
N-terminus upon export via the general Sec-dependent secre-
tion pathway. SAgs are released as non-enzymatic, relatively
small proteins, with the final toxin product ranging in size from
∼22 to 29 kDa. All SAgs are made of two structurally similar
domains, linked through a central α-helix. The larger N-terminal
domain contains a β-barrel motif similar to an OB-fold, while
the smaller C-terminal domain contains the β-grasp motif, which
is similar to immunoglobulin-binding domains (Mitchell et al.,
2000).
Pioneering crystallographic studies with staphylococcal
enterotoxins B in complex with human leukocyte antigen
(HLA)-DR1 (Jardetzky et al., 1994), and SEC3 in complex with
the mouse TCR Vβ8.2-chain (Fields et al., 1996), established a
molecular framework by how SAgs can activate so many T cells
(Li et al., 1999). These studies demonstrated that SAgs bind to
lateral surfaces of both TCRs, and pMHC class II molecules,
to “distort” the normal TCR-pMHC II interaction, such that
the CDR3 loops of both TCR α- and β-chains (which are key
for antigen recognition) are wedged away from the antigenic
peptide (Figures 2B–E). Through this mechanism, activation
of the T cell is no longer antigen specific, but now dependent
upon which Vβs can be bound by that particular SAg explaining
how SAgs are Vβ-specific (Li et al., 1999). Large numbers of
SAg-activated T cells can then release a multitude of proinflam-
matory cytokines which in severe cases may lead to the “cytokine
storm” phenomenon characteristic of TSS (McCormick et al.,
2001). Activation of antigen presenting cells (APCs) by SAgs
also contributes to cytokine release due to the involvement of
MyD88, which upregulates NF-κB, leading to production of
proinflammatory molecules (Kissner et al., 2011).
Recent years have seen a number of further advances in the
structural characterization of the staphylococcal SAgs, and there
is now a broader picture as to how SAgs from the different evolu-
tionary groups (Figure 1) function to distort the normal process
of T cell activation (Figure 2). For example, the Group I SAg
TSST-1 (Figure 2B), which is extremely specific for the human
Vβ2+ T cells (Choi et al., 1989), forms a unique T cell activation
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complex by binding the MHC II α-chain through a relatively
low-affinity interface that is highly influenced by different anti-
genic peptides within MHC II (Kim et al., 1994; Wen et al., 1996).
Also, TSST-1 recognizes unique amino acid insertions from Vβ2
within both CDR2 and framework region (FR) 3, explaining
the extreme Vβ-specificity of this SAg (Moza et al., 2006, 2007;
Rahman et al., 2011). There are no direct TCR-MHC II contacts
in this T cell activation complex. Group II SAgs (Figure 2C) such
as SEB, SEC3, and SpeA, are more “promiscuous” in their Vβ-
targets, and engage TCR Vβ through “conformation-dependent”
mechanisms that are thought to be less dependent on specific
Vβ amino acid side-chains (Fields et al., 1996; Li et al., 1998;
Sundberg et al., 2002). These SAgs bind the MHC II α-chain
through an N-terminal, low-affinity binding domain, yet in con-
trast to TSST-1, this binding is antigenic peptide-independent
(Jardetzky et al., 1994). Group III SAgs (Figure 2D) consist of
only staphylococcal SAgs, and these toxins are thought to be able
to cross-link MHC II molecules (Abrahmsen et al., 1995; Hudson
et al., 1995) through both a low-affinity site similar to Group II,
(Petersson et al., 2002) as well as a high-affinity, zinc-dependent
MHC II β-chain interface located within the β-grasp domain of
the SAg (Petersson et al., 2001). The only structural information
for how Group III SAgs engage TCR is for SEH (Saline et al.,
2010), which represents somewhat of an outlier within Group
III, and is the only known Vα-specific SAg (Petersson et al.,
2003; Pumphrey et al., 2007). Group IV SAgs are restricted to
only streptococcal members, and these toxins bind Vβ similar to
the Group II SAgs, although with a larger footprint (Sundberg
et al., 2002), and contain a high-affinity MHC II β-chain bind-
ing domain similar to Group III (Li et al., 2001). Considerable
evidence indicates the presence of a low-affinity MHC II α-chain
interaction, likely similar to Group II (Swietnicki et al., 2003;
Tripp et al., 2003; Kasper et al., 2008), although this interaction
has not been characterized structurally. The Group V SAgs con-
tain a high-affinity MHC II β-chain binding domain (Fernandez
et al., 2006) similar to Group III, and bind the TCR Vβ with a
more “lateral” position extending into FR4 (Figure 2E) (Gunther
et al., 2007). There is currently no information relating to the
presence, or absence, of the generic low-affinity MHC II interface
with Group V SAgs.
Within the SAg family of toxins, each member is able to
efficiently activate large numbers of T cells, regardless of sub-
tle, or dramatic, differences within the different SAg-mediated
T cell activation complexes. However, the one common struc-
tural feature of all characterized SAgs, with the exception of the
Vα-specific SEH, is the engagement of the Vβ CDR2 loop, and
this loop appears to be the critical determinant for Vβ-specificity
(Rahman et al., 2011).
Recently, it was demonstrated that SEB can bind to the cos-
timulatory molecule CD28, which is constitutively expressed on
naïve T cells and binds B7 ligands on APCs. The CD28 binding
site is divergent from both the TCR andMHC II binding domains
of SEB, and is relatively conserved amongst the SAg family.
Disruption of CD28 binding by peptide antagonists reducedmor-
tality rates in mice administered with D-galactosamine and SEB
by downregulating Th1, but not Th2 cytokines (Arad et al., 2011).
These lines of evidence support the proposal that CD28 binding
by SAgs is important to the function of SAgs. Further research
elucidating downstream mechanisms will clarify the exact role of
CD28 during T cell activation by SAgs.
STAPHYLOCOCCAL SUPERANTIGENS AND DISEASE
STAPHYLOCOCCAL FOOD POISONING
The first disease linked to the staphylococcal SAgs was SFP, and
evidence that a staphylococcal toxin caused the illness dates back
to 1930, where filterable supernatants from a “yellow staphylo-
coccus” was able to induce SFP in human volunteers (Dack et al.,
1930; Jordan, 1930). The role of the staphylococcal SAgs in food-
borne disease has been reviewed recently in detail (Argudin et al.,
2010; Hennekinne et al., 2011), and will not be discussed here.
TOXIC SHOCK SYNDROME
The other human disease clearly caused by the staphylococcal
SAgs is TSS. This disease was described in 1927 by Franklin
Stevens as staphylococcal scarlet fever (Stevens, 1927), and was
named “toxic shock syndrome” by Todd and colleagues in 1978
to describe a systemic illness in seven children caused by non-
invasive S. aureus (Todd et al., 1978). The pathogenesis of TSS
is due to a SAg-induced cytokine storm owing to the massive
activation of T cells in individuals lacking neutralizing antibod-
ies to the particular SAg [reviewed in (McCormick et al., 2001)].
The disease is a capillary leak syndrome where patients develop
fever, rash, hypotension, multiorgan involvement and convales-
cent desquamation (McCormick et al., 2001). S. aureus can cause
the menstrual form of TSS, which historically occurred in young
women in association with high absorbency tampons, and non-
menstrual TSS, which can occur from virtually any S. aureus
infection, although infrequently from bacteremia (McCormick
et al., 2001). Although most staphylococcal SAgs are function-
ally capable of inducing TSS in experimental animals, only a
few select SAgs have historically been associated with the dis-
ease. This is somewhat surprising given the large “collection”
of these extremely potent toxins. The TSST-1 SAg was linked
to the menstrual form of TSS in 1981 (Bergdoll et al., 1981;
Schlievert et al., 1981), although it is also clear that other SAgs,
primarily TSST-1, SEB and SEC, are capable of causing the
non-menstrual form (Bohach et al., 1990; McCormick et al.,
2001).
During the early 1980s, there were a high number of men-
strual TSS cases in young women associated with the use of
high absorbency tampons (Shands et al., 1980) and the esti-
mated incidence of all forms of TSS at this time was 13.7/100,000
(Osterholm and Forfang, 1982). By the mid-1980s, following
the removal of these products from the marker, and public
awareness campaigns as well as product labeling, the overall inci-
dence dropped to 0.53/100,000 with a case-fatality rate of ∼4%
(Gaventa et al., 1989). A recent population based surveillance
for TSS in Minnesota between 2000 and 2006 demonstrates that
this rate has been relatively stable and that TSST-1 was still
the major cause in most cases (DeVries et al., 2011). Of note,
although the community acquired MRSA clonal strain USA300
has dramatically increased in prevalence in the U.S., this strain
does not appear to cause many cases of TSS (DeVries et al.,
2011). Although the overall incidence of TSS appears low, it has
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been suggested that severe SAg-mediated disease remains under-
reported (DeVries et al., 2011), due to both the strict CDC case
definition (Centers for Disease Control and Prevention, 2011) as
well as prompt and appropriatemedical attention that would pre-
vent the most severe forms of SAg intoxication. Indeed, TSS is
still a major problem, and cases of non-menstrual TSS pediatric
burn patients can be extremely dangerous if not recognized early
(White et al., 2005).
Apart from the more overt forms of SAg-mediated diseases,
there is significant evidence that SAgs also can play a role in a
number of other diseases and these will be discussed below.
KAWASAKI DISEASE
Kawasaki Disease (KD) was first described by Tomisaku Kawasaki
in 1967 (Van Crombruggen et al., 2011) and is now the lead-
ing cause of acquired heart disease in children from developed
nations. KD is an acute, self-limiting vasculitis, typically affecting
the coronary arteries, and thought to be triggered by an infec-
tious agent in genetically susceptible individuals (Yeung, 2010).
Although the etiology of KD is not known, there is compelling
evidence that bacterial SAgs are involved, and could be causal
in association with host genetic factors (Matsubara and Fukaya,
2007). First, the clinical presentation of KD has features reminis-
cent of TSS, including fever, a desquamating rash and erythema
of the mucous membranes. SAg producing S. aureus and S. pyo-
genes have been isolated from KD patients, and seroconversion
with anti-SAg antibodies has also been demonstrated. Perhaps the
strongest evidence of SAg involvement however, is the demon-
stration of Vβ skewing in KD patients (Abe et al., 1992). A
number of studies have found primarily Vβ2 expansion (Leung
et al., 1995b) providing a link to either TSST-1 or SpeC which
are both Vβ2 specific (Rahman et al., 2011). Others, however,
have found expansion of various Vβ families (Nomura et al.,
1998; Yoshioka et al., 1999), potentially implicating other SAgs
with different Vβ profiles. Treatment of KD involves the use of
intravenous immunoglobulin (IVIG) (Newburger et al., 1986),
and IVIG is well known to contain SAg neutralizing antibodies
(Darenberg et al., 2004; Schrage et al., 2006). Although there is
no direct evidence to suggest SAg involvement, there also exists
the Kawasaki-like syndrome, which in contrast to KD occurs
primarily in adults with severe immunosuppression including
HIV/AIDS (Stankovic et al., 2007).
CHRONIC RHINOSINUSITIS
Chronic rhinosinusitis (CRS) is a group of disorders characteri-
zed by inflammation of the nose and paranasal sinuses for at
least 3 months duration (Van Crombruggen et al., 2011). CRS can
occur with or without nasal polyps, and accumulated evidence
is now convincing that S. aureus SAgs can contribute to, at least
in some cases, CRS with nasal polyposis (Van Zele et al., 2004).
In this disease, SAgs are thought to skew the cytokine response
towards a TH2 phenotype inducing both eosinophilia and the pro-
duction of polyclonal IgE, which in turn could be further linked
to asthma (Bachert et al., 2010). There is no single SAg associated
specifically to this disease (Van Zele et al., 2008; Heymans et al.,
2010), and as noted (Van Crombruggen et al., 2011), a causal
relationship with S. aureus has not been established.
ATOPIC DERMATITIS
Atopic dermatitis (AD) represents a chronic and relapsing
T cell-mediated inflammatory skin disorder with IgE-mediated
sensitization to allergens. ADmost often affects infants and young
children, but may persist into adulthood, or may first develop
in adults as late-onset AD. AD has both genetic and environ-
mental contributions but nearly all AD patients are colonized by
S. aureus. This is likely due to both the damaged skin barrier
and impaired host immune responses. Significant evidence also
indicates an important role for the staphylococcal SAgs in exac-
erbating the disease [reviewed in (Schlievert et al., 2010)]. SAgs
have long been known to induce the skin homing receptor cuta-
neous lymphocyte-associated antigen (CLA) on T cells to recruit
these cells to the skin (Leung et al., 1995a). Very recent evidence
indicates that skin homing, phenotypically Treg (CD4+ FoxP3+)
cells from AD patients may actually display a TH2 phenotype in
response to SEB stimulation (Lin et al., 2011). AD patients may
also develop anti-SAg IgE antibodies that can further worsen the
condition (Leung et al., 1993; Bunikowski et al., 1999; Lin et al.,
2000). AD is often treated with glucocorticoids and SAgs have
been shown to induce glucocorticoid resistance in PBMCs (Hauk
et al., 2000). A recent study that examined essentially the entire
staphylococcal SAg family found that isolates from steroid resis-
tant AD patients contained significantly more SAgs genes than
isolates from non-steroid resistant patients or menstrual isolates
provoking the idea that steroid treatment may actually select for
SAgs in these strains (Schlievert et al., 2008).
GUTTATE PSORIASIS
Guttate psoriasis is an acute form of psoriasis mediated by autore-
active T cells that typically develops in young adults and children.
This inflammatory skin disease is typically preceded by strepto-
coccal pharyngitis, and the streptococcal SAgs, in particular SpeC,
and Vβ2+ T cells have been implicated (Leung et al., 1995c).
Some associations have also beenmade with S. aureus and chronic
plaque psoriasis (Sayama et al., 1998; Balci et al., 2009).
NASAL COLONIZATION AND STAPHYLOCOCCAL
SUPERANTIGENS
Staphylococcal colonization can be defined by the presence and
multiplication of S. aureus in the absence of infection or dis-
ease. In humans, the anterior nares are the most common area
colonized by S. aureus and the prevalence of nasal colonization
is particularly high within the general population. Individuals
have been typically classified into three separate groups based on
their nasal carriage status: persistent, intermediate, or non-carriers.
Approximately 20% of the general population are persistent car-
riers of S. aureus, ∼30% are intermittent carriers, and ∼50% are
non-carriers (Wertheim et al., 2005). In the event of an infec-
tion, carriers have a better prognosis than non-carriers (von Eiff
et al., 2001; Wertheim et al., 2004); however, nasal colonization
increases the risk of infection by fourfold (Safdar and Bradley,
2008). Furthermore, it is believed that ∼80% of S. aureus blood-
stream infections come from an endogenous source (von Eiff
et al., 2001), and this can be particularly dangerous in a hos-
pital setting if a nasal carrier is immunocompromised and the
colonizing strain is resistant to antibiotics.
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Although a myriad of bacterial factors play a role in determin-
ing nasal colonization, it has not yet been established whether
or not SAgs are involved. Epidemiological studies evaluating
S. aureus SAg gene distribution in nasal swabs compared with
blood isolates concluded that there were no differences between
blood and nasal isolates in the number of toxins, or a correla-
tion to a particular toxin and that toxin gene distribution was
widespread and highly varied (Holtfreter et al., 2007). S. aureus
strains encoding the same SAg genes can produce different
amounts of toxin (Varshney et al., 2009) and this may make cor-
relations difficult in epidemiological studies, which often rely on
genomic typing instead of protein quantification.
The particular molecular switch by how colonized bacteria
become pathogenic is likely a mixture of host-pathogen and
environmental factors that leads to a breach in the mucosa and
subsequent infection. The role of the two-component regula-
tory system agr has been classically associated with dissemination
and the release of secretory proteins and downregulation of sur-
face associated proteins (Recsei et al., 1986). Many SAgs such as
TSST-1 are regulated by agr (Recsei et al., 1986), which appears to
be dampened during colonization, suggesting that agr-controlled
SAgs may not be involved in colonization. This has been further
supported where the constitutive expression of RNAIII, the effec-
tor molecule of the agr system, reduces nasal colonization in rats
(Pynnonen et al., 2011). Thus, it is likely that agr is downregulated
during colonization, which has been demonstrated in human
studies (Burian et al., 2010). It has however, been suggested that
certain SAgs such as staphylococcal enterotoxin A (SEA), which
is not regulated by agr, may play a role early on in coloniza-
tion (Bohach and Schlievert, 2007). Although many persistent
carriers contain the bacteriophage that carries SEA, this genetic
element does not appear to play a role early on during coloniza-
tion (Verkaik et al., 2011). Furthermore, the sea gene has been
correlated with sepsis (Ferry et al., 2005), although the presence of
SEA has yet to be confirmed in blood during sepsis. This work also
demonstrated a correlation between the egc operon of SAgs and
colonization (Ferry et al., 2005). A follow-up study using recom-
binant SAgs found that both types (egc and non-egc) of SAgs
induced similar proliferative activity on PBMCs (Grumann et al.,
2008). However, the proliferative potential of supernatants taken
from patients with strains containing egc genes demonstrated that
strains encoding egc SAgs do not have as high proliferative activ-
ity as strains encoding non-egc SAgs, suggesting that egc SAgs
are not made in quantities as high as non-egc SAgs. A lack of
neutralizing antibodies against egc-encoded SAgs was also found
in serum from healthy humans indicating either a lack of egc
toxins being produced by S. aureus or an inability to produce
neutralizing antibodies by the host (Holtfreter et al., 2004). It is
interesting that only non-egc encoded SAgs have been implicated
in toxin-mediated diseases. Thus, the role of egc-encoded SAgs in
colonization requires further investigation.
It is difficult to directly ascertain whether or not SAgs are pro-
duced in vivo during colonization mainly due to the presence
of S. aureus protein A, which binds the Fc portion of anti-
bodies, thereby causing background levels of assays to be quite
high. However, analysis of the immunological response can pro-
vide important information. In particular, both Vβ-specific T cell
activation and SAg-neutralizing antibodies are indirect ways of
determining if SAgs have encountered the immune system. While
Vβ-skewing has been studied in the context of severe disease
(Ferry et al., 2008b), it has long been known that the general
population develops anti-SAg antibodies capable of neutralizing
these toxins (Vergeront et al., 1983). Also, persistent nasal carri-
ers of S. aureus have been found to have neutralizing antibodies
against the SAgs produced by the colonizing strain (Holtfreter
et al., 2006; Kolata et al., 2011). Levels of neutralizing antibod-
ies against TSST-1 and SEA were significantly higher in persistent
nasal carriers than non-carriers (Verkaik et al., 2009) suggesting
that these SAgs are actively produced during nasal colonization.
To what extent, if any, do SAgs play during colonization has
not yet been experimentally addressed. Intranasal vaccination in
rodents with deactivated TSST-1 was able to decrease mortality
rates from TSST-1 producing S. aureus septic challenge and sig-
nificantly decreased the bacterial load in organs (Narita et al.,
2008). This was a TSST-1 specific response, as challenge with
non-TSST-1 producing S. aureus did not result in a significant
reduction in bacterial load when compared to non-vaccinated
mice. The same vaccination strategy protected against nasal chal-
lenge only during the initial colonization phase (days 1 and 3).
Since the model only evaluated colonization up to day 7, it is dif-
ficult to assess whether or not this is able to have a lasting effect
against S. aureus nasal persistence, since there were not significant
effects at day 5 (Narita et al., 2008).
Staphylococcal peptidoglycan-embedded molecules have been
found to downregulate the immune response stimulated by SAgs
(Chau et al., 2009). This effect was most effective at high cell den-
sities suggesting that it is important in a state of colonization or
a biofilm as opposed to free-living planktonic cells. Thus, if a
colonized population of S. aureus is producing SAgs, any invad-
ing “rogue” cells that are not a part of the main colony may be
killed by an activated immune system, while the dense colony is
able to downregulate this response in the local area to prevent
clearance. This suggests a role for SAgs as checkpoints of dissemi-
nation. Evidence suggests that when SAgs are systemic in the case
of TSS (Ferry et al., 2008b), S. aureus is able to prevent dissem-
ination, which may be partly why bacteremia is rarely associated
with staphylococcal TSS. This is also supported by the observation
that sepsis patients lack Vβ-skewing unlike TSS patients (Ferry
et al., 2008a), suggesting that bacterial dissemination prevents
toxin production.
FUTURE DIRECTIONS FOR RESEARCH
The collective SAg research community has contributed enor-
mously to an advanced understanding of SAg biology. Yet, there
remain a number of important avenues for further study and
consideration.
Although SAgs are defined by Vβ-specificity, different human
MHC II molecules are also clearly important for the response to
SAgs (Yeung et al., 1996; Medina et al., 2001; Kotb et al., 2002;
Llewelyn et al., 2004; Goldmann et al., 2005; Nooh et al., 2007).
Mouse models (such as C57BL/6 and BALBc) have been ham-
pered by the fact that mouse MHC II do not respond in the same
way, and are not as sensitive to SAgs, as human MHC (Yeung
et al., 1996). Alternative models include rabbits that respond
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more appropriately (Parsonnet et al., 1987; Dinges and Schlievert,
2001; Buonpane et al., 2007), as well as transgenic mouse strains
that express human MHC class II molecules (Yeung et al., 1996;
DaSilva et al., 2002). Models of TSS also often utilize a liver-
damaging reagent such as D-galactosamine in conjunction with
high levels of SAgs. Liver and gut pathology has recently been
implicated in the course of TSS in a humanized transgenic HLA-
DR3 mouse model without the use of D-galactosamine (Tilahun
et al., 2011a,b) and thus, D-galactosamine may mask pathologies
normally induced via TSS. Lastly, although many studies using
purified recombinant SAgs have yielded many insights, SAg func-
tion is still rarely studied in the context of live infections using
genetically defined knockout strains. More work using live infec-
tions with appropriate SAg-responsivemodels is needed to be able
to coordinate SAg production with other virulence factors.
Although a number of studies have evaluated the presence of
S. aureus, and correlations of particular SAg genes with particu-
lar clinical syndromes, the presence of the gene does not equate
to expression and function of the actual toxin. Indeed, the origi-
nal discovery of TSST-1 as the causal agent of menstrual TSS was
made due to the high level production of this toxin from men-
strual TSS strains (Bergdoll et al., 1981; Schlievert et al., 1981).
For many human diseases where SAgs may contribute to, or drive
the pathology, there is likely not being a single toxin responsible
given that they can all activate numerous T cells. As we now know
the Vβ skewing patterns of virtually all the known staphylococcal
SAgs (Thomas et al., 2009; Seo et al., 2010; Wilson et al., 2011),
further systematic evaluations focused on SAg expression coupled
with function in relation to particular clinical syndromes (Ferry
et al., 2008b), are warranted.
The large family of SAgs continue to grow, and the YPM and
MAM SAgs seem to have developed their SAg-activity through
convergent evolution as these toxins are not orthologous to the
pyrogenic toxin SAgs, or to each other. Also, the animal model of
KD utilizes an uncharacterized SAg from the cell wall preparation
of Lactobacillus casei to induce the disease in mice (Yeung, 2007).
L. casei is found commonly in the intestinal tract, is widely used
by the dairy industry, and is clearly not a pathogen. It is easy
to speculate that uncharacterized SAgs could be produced by
other microorganisms associated with human immune mediated
sequelae.
Arguably the most interesting question that remains in this
field is why do S. aureus possess such a large, genetically and
antigenically distinct, extremely potent, and seemingly redundant
group of these toxins? SAgs skew responses toward TH1 during
severe disease, but toward TH2 responses during atopic disease
in genetically predisposed individuals. TH1 skewing can result in
delayed development of neutralizing antibody and perhaps this
is an important in vivo survival strategy. Many patients follow-
ing menstrual TSS fail to develop anti-TSST-1 antibodies (Stolz
et al., 1985) so this can occur from TSS. Conversely, humans
clearly develop anti-TSST-1 antibodies such that by age 1, ∼50%
have antibody titers considered to be protective (Vergeront et al.,
1983). An interesting hypothesis has been proposed where exces-
sive T cell expansion may act as a sponge to titrate IL-2 necessary
for further T cell expansion, essentially causing immunosuppres-
sion (Llewelyn and Cohen, 2002). Similarly, massive expansion of
Vβ-specific T cells may induce a loss of overall receptor diversity
filling up the “space,” providing an alternative method of immune
escape. Continued efforts into understanding the complex biol-
ogy of SAgs will undoubtedly answer many of these questions. It
is clear that these remarkable toxins represent a highly unique and
well adapted virulence factor, although the evolutionary function
of these toxin in the life cycle of S. aureus still remains unclear.
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